Line of Therapy Analysis to Support Commercialisation Efforts of Rare Disease

A pharmaceutical company needed reliable real-world evidence to support commercialisation strategy for a pulmonary arterial hypertension (PAH) therapy, since PAH is often delayed or misdiagnosed and requires invasive right heart catheterization to confirm. Symphony Health (an ICON company) built a high-confidence patient cohort in its Integrated Dataverse (IDV®), accounting for ICD-10 coding changes and survival data, and ran a line-of-therapy analysis covering market share by line, time between lines, time from diagnosis to treatment, combination vs. monotherapy, and academic vs. community prescribing differences. The analysis found rising disease awareness and diagnosed patient volumes, that community HCPs prescribe combination therapy less often than academic ones, and that PDE5 inhibitors remain the primary treatment choice alone or in combination across all therapy lines, largely due to brand/generic availability and perceived safety. No specific percentage or count metrics were given in the visible text.

The customer is anonymised in Symphony Health’s own case study — not withheld by us.

Symphony Health is a commercial claims and prescriber-data provider, recently divested from ICON plc to HealthVerity, supplying open/closed claims data for pharma commercial insight.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.